Author(s):
Anuradha Singh, Sultan Ahmad, Manish K. Singh, Babita Kumar, Afreed
Email(s):
anuradhampharm@gmail.com
DOI:
10.52711/2321-5836.2026.00004 
Address:
Anuradha Singh1*, Sultan Ahmad1, Manish K. Singh2, Babita Kumar1, Afreed1
1Sanskar College of Pharmacy and Research, Ghaziabad, Uttar Pradesh, India.
2BN University, Rajasthan, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 1,
Year - 2026
ABSTRACT:
RNA therapeutics have become a revolutionary class of medicines, offering a previously unthinkable precision in targeting genetic and molecular pathways underlying a wide range of diseases. Unlike conventional drugs, RNA-based therapies—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), aptamers, and messenger RNA(mRNA)—can modulate gene expression, silence disease-causing transcripts, Or, with high specificity, substitute proteins that are insufficient. The clinical success of drugs such as Nusinersen, Patisiran, and Pegaptanib, that work well in the body and the groundbreaking creation of mRNA vaccines for COVID-19 has increased interest in RNA systems around the world.Despite significant challenges in delivery, stability, and immunogenicity, advances in lipid nanoparticles, chemical modifications, and conjugate technologies has made them more useful as medicines.Future directions suggest combination technique expanded targeting of previously "undruggable" genes using personalized RNA therapy.There is promise in this new era of precision medicine for more targeted, efficient, and adaptable treatments for genetic disorders, cancer, infectious diseases, and beyond.
Cite this article:
Anuradha Singh, Sultan Ahmad, Manish K. Singh, Babita Kumar, Afreed. RNA Therapeutics: A New Era in Precision Medicine. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 29-4. doi: 10.52711/2321-5836.2026.00004
Cite(Electronic):
Anuradha Singh, Sultan Ahmad, Manish K. Singh, Babita Kumar, Afreed. RNA Therapeutics: A New Era in Precision Medicine. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 29-4. doi: 10.52711/2321-5836.2026.00004 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-1-4
REFERENCES:
1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10): 759-80. doi:10.1038/nrd4278.
2. Dolgin E. The tangled history of mRNA vaccines. Nature. 2021; 597(7876): 318-24. doi:10.1038/d41586-021-02483-w.
3. Kim YK. RNA-based therapeutics: Current status and future perspectives. Exp Mol Med. 2022; 54(5): 529-36. doi:10.1038/s12276-022-00757-5.
4. Choi YC. RNA therapeutics: The use of antisense oligonucleotides and small interfering RNA. Chonnam Med J. 2020; 56(2): 87-91. doi:10.4068/cmj.2020.56.2.87.
5. Cech TR, Steitz JA. The noncoding RNA revolution—trashing old rules to forge new ones. Cell. 2014; 157(1): 77-94. doi:10.1016/j.cell.2014.03.008.
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669): 806-11. doi:10.1038/35888.
7. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018; 27(4): 714-39. doi:10.1016/j.cmet.2018.03.004.
8. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261-79. doi:10.1038/nrd.2017.243.
9. Wurster JI, Ludolph AC. RNA therapeutics: clinical advances and future potential. Nat Rev Drug Discov. 2021; 20(12): 863-82. doi:10.1038/s41573-021-00208.
10. Rothgangl T, Witzel M, Nowrouzi A, Michalakis S. mRNA-based therapies for rare genetic diseases. Hum Gene Ther. 2020; 31(17-18): 1034-44. doi:10.1089/hum.2019.090.
11. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. RNAi-based therapeutics and tumor targeted delivery in cancer. Nat Rev Genet. 2021; 22(5): 323-42. doi:10.1038/s41576-021-00439-4.
12. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Rev Genet. 2021; 22(5): 297-310. doi:10.1038/s41576-021-00439-4.
13. Park J, Kim Y, Lee H, et al. Therapeutic aptamers: Development and prospects. Exp Mol Med. 2022; 54(5): 529-36. doi:10.1038/s12276-022-00757-5.
14. Zhou J, Chen P, Lin J, et al. Advances in RNA-based therapeutics: challenges and strategies for intracellular delivery and stability. Cell Death Dis. 2022; 13: 371. doi:10.1038/s41419-022-05075-2.
15. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8): 541-55. doi:10.1038/nrg3763.
16. Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017; 35(3): 238-48. doi:10.1038/nbt.3765.
17. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2021; 20(6): 429-50. doi:10.1038/s41573-021-00154-0.
18. Yu AM, Tu MJ, Reighard SD, et al. Innate immune responses to RNA therapeutics: Lessons learned and future prospects. Adv Drug Deliv Rev. 2020; 159: 69-87. doi:10.1016/j.addr.2020.03.002.
19. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019; 381(17): 1644-52. doi:10.1056/NEJMoa1813279.
20. Siew A, Tan L, Tan J, et al. Delivery technologies for RNA therapeutics. Nat Rev Drug Discov. 2022; 21: 1015-35. doi:10.1038/s41573-022-00582-4.
21. Fenton OS, Kauffman KJ, McClellan RL, et al. Advances in biomaterials for delivery of mRNA therapeutics: Moving from bench to bedside. Adv Mater. 2018; 30(29): 1705325. doi:10.1002/adma.201705325.
22. Teja Deshpande, Pratap Bhan Kaushik, Ruhan Shaikh, A.V. Tilak. Noncoding RNA Therapeutics: Pioneering a new Frontier. Research Journal of Pharmacy and Technology. 2024; 17(8): 3933-5.
23. Sayyed AA, Vasudevan SS, Ahmad S, Sarker P, Prasad A, Khandelwal S, Choudhary I, Kandrikar TY, Verma A, Ali SA, Gondaliya P, Arya N. Exosomal microRNA for diagnosis and prognosis of head and neck cancer. In: Diagnostic, Prognostic, and Therapeutic Role of MicroRNAs in Head and Neck Cancer. 2024. p. 221-36